Termination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemic
Published Date: 7/2/2026
Notice
Summary
The Secretary of Health and Human Services (HHS) is issuing this notice pursuant to section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C) Act. On February 4, 2020, as amended on March 15, 2023, HHS determined that there is a public health emergency, or significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of U.S. citizens living abroad, and that involves the virus (later referred to as SARS-CoV-2) that causes COVID-19. On the basis of this determination, the HHS Secretary declared that circumstances exist justifying the authorization of emergency use of (1) in vitro diagnostics for detection and/or diagnosis of SARS-CoV-2 (February 4, 2020); (2) personal respiratory protective devices during the COVID-19 outbreak (March 2, 2020); and (3) medical devices, including alternative products used as medical devices (March 24, 2020). On June 29, 2026, the HHS Secretary determined that circumstances no longer exist justifying the authorization of emergency use of these medical devices. On the basis of this determination, the HHS Secretary is terminating these declarations ("EUA declarations"), effective on December 26, 2026.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-12069 — Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflicts of Interest, and Related Provisions
This new rule makes sure the groups that check Medicare providers play fair and follow clear rules to avoid conflicts of interest. It updates how psychiatric hospitals are reviewed and tightens rules for providers who lost their Medicare status but want back in. These changes affect Medicare providers and accrediting groups, start June 16, 2027, and aim to keep care safe and trustworthy.
2026-11530 — Employment and Training Services for Noncustodial Parents in the Child Support Program; Rescission
The government plans to cancel a recent rule that let child support agencies offer job training to noncustodial parents using federal funds. This change affects agencies and parents involved in the child support program and could shift how support services are funded and delivered. Comments on this proposal are open until August 10, 2026, so folks have time to weigh in before it’s final.
2026-11140 — Federal Independent Dispute Resolution Operations
Starting soon, health plans and insurers must share clearer info when they pay or deny surprise medical bills. They’ll use special codes to explain these decisions, especially when dealing with folks they don’t have contracts with. This helps patients and providers understand bills better and speeds up fixing disputes, with no extra costs for most people.
2026-10890 — Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model
Starting July 1, 2026, Medicare is updating the Increasing Organ Transplant Access (IOTA) Model to help kidney transplant hospitals do even better at getting more people transplanted and improving care quality. These changes affect hospitals involved in kidney transplants and aim to make the process smoother and more effective, with new payment rules that reward success. This update is part of a 6-year plan running through 2031 to save more lives and boost patient experience.
2026-10292 — Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments
This proposed rule changes how states can pay Medicaid managed care plans and certain doctors to make sure payments are fair, efficient, and encourage enough providers to offer quality care. It affects states, Medicaid managed care organizations, and targeted Medicaid practitioners, aiming to keep payments balanced and services available. Comments on these changes are open until July 21, 2026, so stakeholders have time to weigh in before it’s finalized.
Previous / Next Documents
Previous: 2026-13369 — Submission for Office of Management and Budget Review; Office of Refugee Resettlement Annual Survey of Refugees
Next: 2026-13374 — Termination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemic
The U.S. Department of Health and Human Services is ending the special emergency rules that allowed quick use of COVID-19 drugs and vaccines. This change affects companies, healthcare workers, and patients who relied on these emergency approvals. The emergency use authorization will officially stop on June 29, 2027, giving everyone time to adjust without sudden disruptions or extra costs.